AKBA NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Akebia Ther · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 1.32 USD
8.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 4.0% above the Trend Line and sits at 16.8% of its 52-week range. The latest completed week returned 8.2%, after a 6.5% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 35 out of 100
Latest Close 1.32 USD 31 Jul 2026
1W Return 8.2% latest completed week
4W Return 6.5% short-term follow-through
12W Return 13.8% quarterly tape
Trend Breadth 13.5% 7 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.2% Latest completed week; four-week move 6.5%. Indicator stack 7/100 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 52/100 conviction; expected move 30.8%. News sentiment 54/100 45 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 4.0% above the Trend Line and sits at 16.8% of its 52-week range. The latest completed week returned 8.2%, after a 6.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1812-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.18Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 6.5% over four weeks, 13.8% over 12 weeks, and -64.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.2%
4W6.5%
12W13.8%
26W-6.4%
52W-64.5%
Active trend streak0 weeks
Active weeks in one year7
Trend breadth13.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.75Latest activity-pressure read.
Pressure change1778.2%Four-week change in activity pressure.
Leadership-32.67Latest relative-leadership reading.
RS change29.0%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength65/100Blend of value, momentum, and quality. Underlying universe rank 36; rank 1 is best.
Value73/100Relative valuation strength. Underlying universe rank 28; rank 1 is best.
Quality77/100Profitability and accounting quality. Underlying universe rank 24; rank 1 is best.
Momentum3/100Medium-term price momentum. Underlying universe rank 98; rank 1 is best.
Growth82/100Revenue and earnings growth. Underlying universe rank 19; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
1.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
34.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
80.9%
Gross profit retained from each unit of revenue.
Operating margin
-3.0%
Operating profit retained from revenue.
Free-cash-flow margin
26.2%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
25.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.6%
Net share repurchases relative to market value.
Shareholder yield
-0.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
26.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

AKBA shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.02, expected move of 30.8%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move30.8%
Put/call volume0.02
Pressure100
Speculation3
Volatility96
Trend agreement0
Open options detail
Insider activity12 / 1

12 acquisitions and 1 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 45 relevant articles.

9 positive · 36 neutral · 0 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move30.8%Nearest-chain priced movement where available.
52-week drawdown-65.2%Distance below the 52-week high.
13-week volatility9.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2614 weeks finished lower.
Best week+15.7%Week of 19 Jun.
Worst week-17.1%Week of 8 May.
Latest week+8.2%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks1
Modest losses7
Sharp losses7
Recent vol9.4%13-week weekly-return volatility.
Base vol7.9%52-week weekly-return volatility.
Up/down split17/31Count of positive and negative weeks in the 52-week window.
Average skew6.5% / -6.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape29/100

Trend, activity pressure, participation, and risk combine to a 29/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 8/12, relative leadership 0/12.

Activity pressure 0.18; No reversal markers Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 76; Small Cap Core rank 71 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options35/100

AKBA shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.02, expected move of 30.8%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 30.8% Sentiment54/100

Weighted news tone is neutral across 45 relevant articles.

Akebia Therapeutics (AKBA) to Announce Earnings on Thursday Insiders12 / 1

12 acquisitions and 1 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.32 USD8.2%1.27 USD1.75 USD0.75-32.6710.7MOff
24 Jul 20261.22 USD-9.0%1.28 USD1.75 USD0.66-39.4010.0MOff
17 Jul 20261.34 USD-4.3%1.29 USD1.75 USD0.57-36.3813.6MOff
10 Jul 20261.40 USD12.9%1.30 USD1.75 USD0.38-38.2527.5MOff
3 Jul 20261.24 USD8.8%1.31 USD1.75 USD0.04-46.0420.8MOff
26 Jun 20261.14 USD6.5%1.32 USD1.75 USD-0.21-51.3526.3MOff
19 Jun 20261.07 USD15.7%1.34 USD1.74 USD-0.32-57.6440.5MOff
12 Jun 20260.92 USD-1.2%1.35 USD1.74 USD-0.24-63.5733.7MOff
5 Jun 20260.94 USD-8.3%1.38 USD1.75 USD-0.13-63.3918.8MOff
29 May 20261.02 USD0.0%1.41 USD1.75 USD0.13-63.0911.4MOff
22 May 20261.02 USD-3.8%1.45 USD1.75 USD0.38-62.8748.7MOff
15 May 20261.06 USD-8.6%1.52 USD1.75 USD0.49-61.7623.1MOff
8 May 20261.16 USD-17.1%1.58 USD1.75 USD0.66-59.0025.8MOff
1 May 20261.40 USD-2.1%1.64 USD1.75 USD0.67-48.6910.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.